Putting insulin glargine and malignancies into perspective

Oncologist

Volumn 14, Issue 12, 2009, Pages 1169-1174

  Ehninger, Gerhard ^a   Schmidt, Alexander H ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Breast; Colon; Glargine; Insulin; Malignancy; Pancreas

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SULFONYLUREA DERIVATIVE;

ADVERSE OUTCOME; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN TREATMENT; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS CANCER; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS; PROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 75449116394     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0206     Document Type: Note

References (24)

1. Pocock SJ, Smeeth L. Insulin glargine and malignancy: An unwarranted alarm. Lancet 2009;374:511-513.
2. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A et al. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer 2005;92:2076 -2083.
3. Larsson S, Mantzoros C, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer 2007;121:856-862.
4. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst 2005;97:1679 -1687.
5. Bowker SL, Majumdar SR, Veugelers P et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254 -258.
6. Kurtzhals P, Schaffer L, Sørensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000;49:999 -1005.
7. Agin A, Jeandidier N, Gasser F et al. Glargine blood biotransformation: In vitro appraisal with human insulin immunoassay. Diabetes Metab 2007;33: 205-212.
8. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009;52:1732-1744.
9. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699 -1708.
10. Jonasson JM, Ljung R, TalbäckMet al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009;52:1745-1754.
11. SDRN Epidemiology Group. Use of Insulin Glargine and Cancer Incidence in Scotland: A Study From the Scottish Diabetes Research Network Epidemiology Group, 2009. Available at http://webcast.easd.org/press/glargine/ download/090818Colhounacceptedpaperadjusted.pdf, accessed July 10, 2009.
12. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766 -1777.
13. Calle EE, Rodriguez C, Walker-Thurmond K et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638.
14. Renehan AG, Tyson M, Egger M et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569 -578.
15. Erbel S, Reers C, Eckstein VW et al. Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 2008;31:1105-1111.
16. Rosenstock J, Fonseca V, McGill JB et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study. Diabetologia 2009;52:1971-1973.
17. McMaster University. Research Team Responds to Concerns About International Insulin Drug Trial. McMaster University news release, August 10, 2009. Available at http://fhs.mcmaster.ca/main/news/news-2009/origin- trial.html, accessed August 22, 2009.
18. Grill M. Dünger für Krebszellen. Der Spiegel 2009;104:104 -107.
19. Rummel A. Erhöht Lantus das Krebsrisiko? TV-Das Erste, July 13 2009, 11-16.
20. German Society for Haematology and Oncology. Keine Steigerung des Krebsrisikos durch Insulin Lantus [press release], July 15, 2009.
21. Institute for Quality and Efficiency in Health Care. Abschlussbericht: Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2. Cologne, Germany: IQWiG, 2009. Available at http://www.iqwig.de/ download/A05- 03-Abschlussbericht-Langwirksame-Insulinanaloga-bei-Diabetes-mellitus-Typ-2-V1. 1.pdf, accessed August 22, 2009.
22. Horvath K, Jeitler K, Berghold A et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(2):CD005613.
23. Wood L, Egger M, Gluud LL et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: Meta-epidemiological study. BMJ 2008;336:601- 605.
24. European Medicines Agency Press Office. Press Release: European Medicines Agency Update on Safety of Insulin Glargine. London, July, 23, 2009. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/Lantus/47063209en.pdf, accessed August 4, 2009.